Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03450083 · ClinicalTrials.gov registry record · Phase 2
Benralizumab Effect on Severe Chronic Rhinosinusitis With Eosinophilic Polyposis
A Phase 2 study, sponsored by Johns Hopkins University.
- Completed
- Registry status
- Phase 2
- Development phase
- 33
- Enrollment target
NCT03450083: Completed Phase 2 study, sponsored by Johns Hopkins University.
NCT03450083 is a Phase 2 study that has completed, run by Johns Hopkins University. The registered enrollment target is 33 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03450083, a Phase 2 study, has completed, sponsored by Johns Hopkins University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 33 participants
- Enrollment target
Study Summary
Benralizumab will be used in a placebo controlled randomized study to treat severe chronic rhinosinusitis with nasal polyps
Interventions
- DRUG Placebo
- DRUG Benralizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2017-07-01 |
| Est. Completion | 2020-02-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03450083
The ClinicalTrials.gov registry entry for NCT03450083 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 33 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Johns Hopkins University, which has 1,448 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03450083 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03450083 about?
NCT03450083 is a clinical study titled "Benralizumab Effect on Severe Chronic Rhinosinusitis With Eosinophilic Polyposis". Benralizumab will be used in a placebo controlled randomized study to treat severe chronic rhinosinusitis with nasal polyps
What is the current status of trial NCT03450083?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 33 participants. The study started on 2017-07-01. Estimated completion is 2020-02-01.
What interventions are being tested in trial NCT03450083?
The interventions under investigation include: Placebo (DRUG), Benralizumab (DRUG).
Who is sponsoring clinical trial NCT03450083?
This trial is sponsored by Johns Hopkins University, which has 1,448 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.